|Day Low/High||5.60 / 6.00|
|52 Wk Low/High||2.45 / 10.24|
Achieving Certification is Key Step for Planned Commercial Launch in the Second Half of 2017
Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Study results in encouraging AUC ROC score of .92, follow up study underway
Poster Presentation on December 9, 2016 at 5:00pm CT
Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in OncoCyte
Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compliant Laboratory Build-Out
Conference Call to Discuss the Results at 5:00 p.m. ET
Expects to Complete the Studies Later this Year and Continues to Project Commercial Launch in the First Half of 2017
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and provided a...